CB2 Insights Completes Full-Scale Platform to Connect Disparate Data Systems
CB2 Insights announced its core technology platform, Sail, is now primed for streamlining and aggregating disparate healthcare data systems.
CB2 Insights (CSE:CBII, OTCQB:CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, today announced its core technology platform, Sail, is now primed for streamlining and aggregating disparate healthcare data systems to enable current and future partners to make faster and smarter business decisions.
“As is often seen in healthcare, managing multiple, disparate systems is a large and expensive barrier and often leads to failed attempts at making solid business decisions. At CB2 we are committed to be the leading company for streamlining, measuring, and generating insightful data to make improvements for the maturing global medical cannabis industry,” said Prad Sekar, CEO, CB2 Insights. “Our Sail platform, which has been used to collect and analyse millions of data points from hundreds of thousands of medical patients using cannabinoid therapy, is now able to integrate full data inputs from Electronic Medical Record (EMR), dispensary, pharmacy systems, and clinical research systems upon which to produce actionable insights.”
CB2 Insights has active partnerships in North America, the UK and Colombia which have acted as the catalyst to synergize its multiple technology platforms such as its electronic data capture (EDC) software, its clinical data management system (CDMS), and its dispensary loyalty platform (TokeIn), in order to create a single, comprehensive platform that will now centralize all existing and external systems to support Real World Evidence (RWE) data collection and clinical trial studies for its growing, international client base.
“CB2 Insights will deploy the industry’s first cannabinoid-focused healthcare data aggregation tool to serve multiple stakeholders across the cannabis and life sciences industries by integrating data from a myriad of sources,” said Kash Qureshi, President & CTO, CB2 Insights. “The data lake will integrate a variety of distinct raw data sets sourced from clinical assets, dispensaries, cannabis companies and other key industry suppliers. Raw anonymized data will be ingested and catalogued, creating a repository that in turn will be a single source to generate insights which can be reviewed and tested over indefinitely and will be key to improving research projects moving forward.”
As a health information technology and clinical research firm focusing on improving patient outcomes, many companies of its kind in other focus areas can often struggle to organize multiple, unstructured data sources which result in timely and costly projects. Organizations such as IQVIA, the largest such company in the industry, has found major success though its IMS Health arm which has excelled in collecting, managing, cleaning and analysing data from multiple disparate sources into a single health information technology system. CB2 Insights is proud to have brought the same methodology and technology strength to the medical cannabis sector.
Earlier this year, CB2 Insights announced that it had secured technology and data focused partnerships with Premier Health Group, UK-based Drug Science, MyAccess Clinics, VIVO Cannabis and FCM Global in Colombia.
About CB2 Insights
CB2 Insights (CSE:CBII) is a global leader in clinical operations, technology & analytics solutions and research and development services with a mission to mainstream medical cannabis into traditional healthcare. Providing immediate market access through its wholly-owned clinical network across 12 jurisdictions, proprietary data-driven technology solutions and comprehensive contract research services designed for those in both the medical cannabis and traditional life sciences industries, CB2 Insights is able to support its partners across the entire data and research spectrum.
CB2’s Clinical Operations business unit leverages extensive experience to develop clinical models with standard operating procedures, advanced workflows, training and ongoing management support. CB2 also owns and operates its own speciality clinics including the brands Canna Care Docs and Relaxed Clarity which assess nearly 100,000 patients seeking medical cannabis treatment to provide immediate market access to US-based product manufacturers for clinical trial and research programs.
The Company has built both electronic data capture (EDC) and clinical data management software (CDMS) which work to support its partners of any size to execute their data and clinical strategies.
CB2 also offers comprehensive contract research organization (CRO) services including full scale clinical trial management, trial design, monitoring and other key research functions used by licensed producers, multi-state operators and traditional pharmaceutical companies entering the medical cannabis space.
For more information please visit www.cb2insights.com.
Kim Nguyen – Director, Investor Relations
1.855.874.4999 ext. 120
Forward Looking Statements
Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in CB2’s filings with Canadian securities regulators. When used in this news release, words such as “will, could, plan, estimate, expect, intend, may, potential, believe, should,” and similar expressions, are forward-looking statements.
Forward-looking statements may include, without limitation, statements regarding the opportunity to provide services and software to the U.S. cannabis industry.
Although CB2 has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are subject to inconsistent legislation and regulation; change in laws; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and recreational-use marijuana industry and; regulatory or political change.
There can be no assurance that such information will prove to be accurate or that management’s expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.
Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. CB2 disclaims any intention or obligation to update or revise such information, except as required by applicable law, and CB2 does not assume any liability for disclosure relating to any other company mentioned herein.
No securities regulator or exchange has reviewed, approved, disapproved, or accepts responsibility for the content of this news release.